Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series
Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series
复制标题
DOI：
10.1007/s00330-006-0461-5
复制
发表时间：
2007-03-01
影响因子：
5.9
通讯作者：
Yoo, Byung Chul
中科院分区：
文献类型：
--
作者：
Choi, Dongil;Lim, Hyo K.;Yoo, Byung Chul
本研究的目的是评估经皮射频消融（RFA）治疗早期肝细胞癌（HCC）患者的长期生存结果和并发症。在1999年4月至2005年5月期间，570例患者（674例早期HCC）在一家机构接受了经皮射频消融作为一线治疗选择。我们评估了有效率、局部肿瘤进展率、生存率和并发症。我们还使用考克斯比例风险模型评估了生存率的预后价值。主要技术有效率为96.7%（652/674）。1年、2年和3年时局部肿瘤进展的累积率分别为8.1%、10.9%和11.8%。1、2、3、4和5年的累积生存率分别为95.2%、82.9%、69.5%、60.8%和58.0%。1998年，中国人民解放军总政治部（
The purpose of this study was to evaluate the long-term survival results and complications of percutaneous radiofrequency ablation (RFA) in patients with early-stage hepatocellular carcinoma (HCC). Between April 1999 and May 2005, 570 patients with 674 early-stage HCCs underwent percutaneous RFA as a first-line treatment option in a single institution. We evaluated the effectiveness rates, local tumor progression rates, survival rates, and complications. We also assessed the prognostic values of survival rates by using Cox proportional hazard models. The primary technique effectiveness rate was 96.7% (652 of 674). The cumulative rates of local tumor progression at 1, 2, and 3 years were 8.1%, 10.9%, and 11.8%, respectively. The cumulative survival rates at 1, 2, 3, 4, and 5 years were 95.2%, 82.9%, 69.5%, 60.8%, and 58.0%, respectively. Patients with Child-Pugh class A cirrhosis, of younger age (